595 related articles for article (PubMed ID: 22766356)
21. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients.
Bouchat S; Gatot JS; Kabeya K; Cardona C; Colin L; Herbein G; De Wit S; Clumeck N; Lambotte O; Rouzioux C; Rohr O; Van Lint C
AIDS; 2012 Jul; 26(12):1473-82. PubMed ID: 22555163
[TBL] [Abstract][Full Text] [Related]
22. Which therapeutic strategy will achieve a cure for HIV-1?
Cillo AR; Mellors JW
Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
[TBL] [Abstract][Full Text] [Related]
23. The role of cytokines in the establishment, persistence and eradication of the HIV reservoir.
Vandergeeten C; Fromentin R; Chomont N
Cytokine Growth Factor Rev; 2012; 23(4-5):143-9. PubMed ID: 22743037
[TBL] [Abstract][Full Text] [Related]
24. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
[TBL] [Abstract][Full Text] [Related]
25. Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?
Vignesh R; Shankar EM
EBioMedicine; 2017 Oct; 24():20-21. PubMed ID: 28865747
[No Abstract] [Full Text] [Related]
26. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
Chun TW; Carruth L; Finzi D; Shen X; DiGiuseppe JA; Taylor H; Hermankova M; Chadwick K; Margolick J; Quinn TC; Kuo YH; Brookmeyer R; Zeiger MA; Barditch-Crovo P; Siliciano RF
Nature; 1997 May; 387(6629):183-8. PubMed ID: 9144289
[TBL] [Abstract][Full Text] [Related]
27. A broad drug arsenal to attack a strenuous latent HIV reservoir.
Stoszko M; Ne E; Abner E; Mahmoudi T
Curr Opin Virol; 2019 Oct; 38():37-53. PubMed ID: 31323521
[TBL] [Abstract][Full Text] [Related]
28. Select host restriction factors are associated with HIV persistence during antiretroviral therapy.
Abdel-Mohsen M; Wang C; Strain MC; Lada SM; Deng X; Cockerham LR; Pilcher CD; Hecht FM; Liegler T; Richman DD; Deeks SG; Pillai SK
AIDS; 2015 Feb; 29(4):411-20. PubMed ID: 25602681
[TBL] [Abstract][Full Text] [Related]
29. Can HIV infection be eradicated through use of potent antiviral agents?
Josefsson L; Dahl V; Palmer S
Curr Opin Infect Dis; 2010 Dec; 23(6):628-32. PubMed ID: 20847693
[TBL] [Abstract][Full Text] [Related]
30. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.
Walker-Sperling VE; Pohlmeyer CW; Tarwater PM; Blankson JN
EBioMedicine; 2016 Jun; 8():217-229. PubMed ID: 27428432
[TBL] [Abstract][Full Text] [Related]
31. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.
Choi BS; Lee HS; Oh YT; Hyun YL; Ro S; Kim SS; Hong KJ
AIDS; 2010 Feb; 24(4):609-11. PubMed ID: 20154582
[TBL] [Abstract][Full Text] [Related]
32. Ingenol derivates promising for HIV eradication.
Poveda E
AIDS Rev; 2014; 16(4):246. PubMed ID: 25373349
[TBL] [Abstract][Full Text] [Related]
33. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
[TBL] [Abstract][Full Text] [Related]
34. Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors.
Ylisastigui L; Coull JJ; Rucker VC; Melander C; Bosch RJ; Brodie SJ; Corey L; Sodora DL; Dervan PB; Margolis DM
J Infect Dis; 2004 Oct; 190(8):1429-37. PubMed ID: 15378435
[TBL] [Abstract][Full Text] [Related]
35. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
Suryawanshi P; Bagul R; Shete A; Thakar M
Front Immunol; 2021; 12():663919. PubMed ID: 33995393
[TBL] [Abstract][Full Text] [Related]
36. Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.
Peng W; Hong Z; Chen X; Gao H; Dai Z; Zhao J; Liu W; Li D; Deng K
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094131
[TBL] [Abstract][Full Text] [Related]
37. The search for a cure for persistent HIV reservoirs.
Lafeuillade A; Stevenson M
AIDS Rev; 2011; 13(2):63-6. PubMed ID: 21587339
[TBL] [Abstract][Full Text] [Related]
38. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
Kim Y; Anderson JL; Lewin SR
Cell Host Microbe; 2018 Jan; 23(1):14-26. PubMed ID: 29324227
[TBL] [Abstract][Full Text] [Related]
39. What can we do to reduce the viral reservoir in HIV-1-infected individuals?
Pohlmeyer CW; Walker-Sperling VE; Blankson JN
Future Microbiol; 2016 Jul; 11():839-42. PubMed ID: 27416850
[No Abstract] [Full Text] [Related]
40. HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'.
Cohen J
Science; 2005 Aug; 309(5737):999-1000. PubMed ID: 16099956
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
